New drug duo aims to shrink advanced kidney tumors

NCT ID NCT05256472

Completed Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This phase 2 trial is testing a new drug called cadonilimab (AK104), either alone or combined with axitinib, as a first treatment for advanced or metastatic kidney cancer. The study includes two parts: one testing different doses of cadonilimab alone in various kidney cancer types, and another testing the combination in clear cell kidney cancer. The main goal is to see how many patients' tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cadonilimab (AK104) and axitinib
What this could lead to: If successful, this combination could offer a new first-line treatment option for advanced kidney cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong: This is an early-phase trial with only 28 participants, so results may not apply to all patients. Side effects from immunotherapy and targeted therapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FIRST LINE TREATMENT RENAL CELL CARCINOMA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.